KPTI logo

Karyopharm Therapeutics Inc.


KPTI: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.


Show KPTI Financials

Consumer Interest
SEC Filings

Recent trades of KPTI by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by KPTI's directors and management

Government lobbying spending instances

  • $40,000 Jan 21, 2020 Issue: Pharmacy
  • $60,000 Oct 21, 2019 Issue: Pharmacy
  • $60,000 Jul 22, 2019 Issue: Pharmacy
  • $60,000 Apr 22, 2019 Issue: Pharmacy
  • $60,000 Jan 23, 2019 Issue: Pharmacy
U.S. Patents

New patents grants

Quiver Logo

No new patents for this ticker

U.S. Patents Dashboard
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of KPTI in WallStreetBets Daily Discussion


Recent insights relating to KPTI

CNBC Recommendations

Recent picks made for KPTI stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in KPTI

Corporate Flights

Flights by private jets registered to KPTI